|
FR3046933B1
(fr)
*
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
US11597706B2
(en)
|
2016-04-18 |
2023-03-07 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
CA3047336A1
(en)
|
2017-01-23 |
2018-07-26 |
Jecure Therapeutics, Inc. |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
AU2017416068A1
(en)
|
2017-05-24 |
2019-10-31 |
The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Novel compounds and uses
|
|
US11465992B2
(en)
|
2017-07-07 |
2022-10-11 |
Inflazome Limited |
Sulfonamide carboxamide compounds
|
|
US11370776B2
(en)
|
2017-07-07 |
2022-06-28 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
|
|
RS65492B1
(sr)
|
2017-07-24 |
2024-05-31 |
Novartis Ag |
Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
|
|
CN111094242B
(zh)
*
|
2017-07-24 |
2024-02-09 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
US11542255B2
(en)
|
2017-08-15 |
2023-01-03 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
|
|
MX2020001776A
(es)
|
2017-08-15 |
2020-03-24 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
|
|
WO2019034693A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
KR20200087759A
(ko)
*
|
2017-11-09 |
2020-07-21 |
인플라좀 리미티드 |
신규한 설폰아마이드 카복스아마이드 화합물
|
|
US12221434B2
(en)
|
2017-11-09 |
2025-02-11 |
Inflazome Limited |
Sulfonamide carboxamide compounds
|
|
US12168653B2
(en)
|
2018-03-02 |
2024-12-17 |
Inflazome Limited |
Sulfonamide derivates as NLRP3 inhibitors
|
|
EP3759077A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
US11834433B2
(en)
|
2018-03-02 |
2023-12-05 |
Inflazome Limited |
Compounds
|
|
GB201803394D0
(en)
*
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
CR20200588A
(es)
|
2018-05-04 |
2021-06-24 |
Inflazome Ltd |
Compuestos novedosos
|
|
US20220267276A1
(en)
*
|
2018-07-03 |
2022-08-25 |
Novartis Ag |
Nlrp modulators
|
|
CN112654350A
(zh)
*
|
2018-07-03 |
2021-04-13 |
诺华股份有限公司 |
使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
|
|
EP3817815A1
(en)
*
|
2018-07-03 |
2021-05-12 |
Novartis AG |
Nlrp modulators
|
|
EP3823974A1
(en)
|
2018-07-20 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Sulfonimidamide compounds as inhibitors of interleukin-1 activity
|
|
SG11202012159TA
(en)
|
2018-07-20 |
2021-01-28 |
Hoffmann La Roche |
Sulfonylurea compounds as inhibitors of interleukin-1 activity
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
US12187702B2
(en)
|
2018-08-15 |
2025-01-07 |
Inflazome Limited |
Sulfonamideurea compounds
|
|
CN113056451A
(zh)
*
|
2018-10-24 |
2021-06-29 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
CN113015730A
(zh)
*
|
2018-11-13 |
2021-06-22 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
EP3880666B1
(en)
|
2018-11-13 |
2023-06-28 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
CR20210235A
(es)
*
|
2018-11-13 |
2021-06-30 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
|
|
US20230059136A1
(en)
*
|
2018-11-16 |
2023-02-23 |
Novartis Ag |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
CN120208846A
(zh)
|
2019-01-14 |
2025-06-27 |
载度思生命科学有限公司 |
经取代的磺酰脲类衍生物
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
CN111848461A
(zh)
*
|
2019-04-29 |
2020-10-30 |
苏州大学 |
Nlrp3炎症小体抑制剂及其制备方法和应用
|
|
AU2020296829B2
(en)
*
|
2019-06-17 |
2026-01-15 |
Olatec Therapeutics Llc |
Method for treating asthma
|
|
US20220378801A1
(en)
|
2019-06-21 |
2022-12-01 |
Ac Immune Sa |
Novel compounds
|
|
WO2021002887A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
JP7595642B2
(ja)
|
2019-07-17 |
2024-12-06 |
ズーマゲン バイオサイエンシーズ エルティーディー |
Ｎｌｒｐ３モジュレーター
|
|
AU2020312800B2
(en)
*
|
2019-07-17 |
2026-04-23 |
Zomagen Biosciences Ltd |
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
|
|
EP4013761A1
(en)
|
2019-08-16 |
2022-06-22 |
Inflazome Limited |
Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
CN111100042B
(zh)
*
|
2019-11-18 |
2022-05-31 |
苏州诚和医药化学有限公司 |
一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
|
|
CN111018750B
(zh)
*
|
2019-12-19 |
2022-05-27 |
苏州诚和医药化学有限公司 |
一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
JP2023513935A
(ja)
|
2020-02-18 |
2023-04-04 |
インフレイゾーム リミテッド |
化合物
|
|
KR20220154165A
(ko)
*
|
2020-03-16 |
2022-11-21 |
조마젠 바이오사이언시즈 엘티디 |
Nlrp3 조절제
|
|
WO2021185912A1
(en)
|
2020-03-19 |
2021-09-23 |
Softhale Nv |
Method for the treatment nlrp3-associated diseases
|
|
US12428391B2
(en)
|
2020-06-11 |
2025-09-30 |
Cisen Pharmaceutical Co., Ltd |
Dimethylsulfoximine derivative
|
|
MX2022014709A
(es)
|
2020-06-19 |
2022-12-16 |
Ac Immune Sa |
Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3).
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
JP7825294B2
(ja)
*
|
2021-02-10 |
2026-03-06 |
ハンジョウ イノゲート ファーマ カンパニー リミテッド |
Ｎｌｒｐ３阻害剤としての化合物
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CN116635374B
(zh)
*
|
2021-05-10 |
2025-05-06 |
康百达（四川）生物医药科技有限公司 |
酰胺衍生物及其应用
|
|
CN118355000A
(zh)
*
|
2021-12-03 |
2024-07-16 |
辰欣药业股份有限公司 |
二甲基亚磺酰亚胺衍生物的盐型及晶型
|
|
CN118541366A
(zh)
|
2021-12-22 |
2024-08-23 |
Ac免疫有限公司 |
二氢噁唑衍生物化合物
|
|
JP2025524640A
(ja)
|
2022-07-14 |
2025-07-30 |
エーシー・イミューン・エス・アー |
Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
|
|
CA3261365A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
NEW COMPOUNDS
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
KR20260027946A
(ko)
|
2023-06-02 |
2026-03-03 |
머크 샤프 앤드 돔 엘엘씨 |
Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|